SYNAIRGEN PLC (SNG)

SYNAIRGEN PLC (SNG)

Seminars

ShareSoc Growth Company Seminar, London, September 2014

Click here Synairgen Stockopedia Report Click here Service Power Stockopedia Report Click here Nature Group Stockopedia Report Click here Chapel Down Stockopedia Report

Blog posts

ShareSoc Growth Company Seminar Announcement

The line-up for our next seminar at which public companies will be presenting on the 17th September is now complete and is given below. This event is in the City of London (at a different venue to normal), with registration starting at 4.00 pm. Four companies will be presenting this month and answering your questions, which are: - Synairgen (SNG): A respiratory drug development company. - Chapel Down Winery (CDGP): England's leading wine producer. - Nature Group (NGR): Marine pollution and offshore waste processing. - ServicePower (SVR): Field service software solutions. Refreshments and a buffet ...

AGM Reports

Synairgen (SYN) AGM Report 2019

The Synairgen 2019 AGM was held on Monday 2nd June at the offices of Fladgate LLP, 16 Great Queen Street, London. For anyone who is unfamiliar with the company, Synairgen is an AIM listed UK based biotech company focused primarily on developing new treatments for Asthma, COPD and other respiratory diseases. The company floated on AIM in November 2004, issuing approximately 8m shares at 130p/share valuing the company at around £28m. There have been several placings since the IPO; the most recent ...

Synairgen (SNG) AGM 2018

I attended the Synairgen AGM last Friday (June 22nd 2018), which was held at the offices of Fladgate LLP, 16 Great Queen Street, London. For investors who is unfamiliar with the company, Synairgen is an AIM listed UK based biotech company focused primarily on developing new treatments for Asthma, COPD and other respiratory diseases. The company floated on AIM in November 2004, issuing approximately 8m shares at 130p/share valuing the company at around £28m. There have been several placings since the IPO ...

Synairgen (SNG) AGM 2016

I attended the Synairgen AGM earlier this week (Tuesday June 14th) which was held at the offices of Fladgate LLP, 16 Great Queen Street, London. For anyone who is unfamiliar with the company, Synairgen are an AIM listed UK based biotech focused on developing new treatments for Asthma, COPD and other respiratory diseases. Their current market cap is around £26M. Synairgen currently have one compound undergoing a confirmatory Phase II clinical study in asthma (funded entirely by Astra Zeneca) and a second ...